Second REDDIE Stakeholder Meeting
Madrid/Spain, 8 September 2024
REDDIE (Real-World Evidence for Decisions in Diabetes) aims to explore how RWD can complement RCTs to improve the efficacy, safety, and value for money of technologies to prevent and treat diabetes. To secure the best possible outcome for the project, expert stakeholders were invited to the second REDDIE Stakeholder meeting on September 8, 2024.
The Stakeholder meeting was held in connection with the upcoming EASD annual meeting in Madrid at the IFEMA Exhibition Center. The main objective of the meeting was to focus on REDDIE’s goal of developing standards to use real-world and synthetic data to bring technologies to people with diabetes. The main chair was Pratik Choudhary, WP2 leader from the University of Leicester with moderation help from Martina Radanović, WP7 Leader from EURICE.
The meeting provided an opportunity to evaluate the real-world impact of the REDDIE project, ensuring that our work continues to address the challenges in diabetes treatment effectively. By bringing together healthcare professionals, policymakers, and those directly affected by diabetes, we shared our progress and received crucial feedback to guide our next steps.
Stakeholders had the opportunity to hear more about the updates from each of the currently resulting work package leaders and evaluate if their work is on the right track. The meeting started with WP2 research associate Jonah Thomas explaining the next steps of the REDDIE Databases dashboard. Christian Torp-Pedersen, WP4 leader from NOH, shared the first results from the RWD analysis made by the group and gathered feedback from the stakeholders.
Martina Vettoretti, WP5 leader from UNIPD, presented the current status of using AI in enhancing clinical trials with real-world and virtual evidence. If you are interested in the first steps from WP5, you can see more on the REDDIE Publications page. The last presentation was from Monika Cigler, the project manager from the coordinating institution Medical University of Graz, about WP6 work with the engagement of regulators, payers, industry and people living with diabetes.
“Anyone who engages with various stakeholders knows that opportunities to talk with them in person are rare. The meeting aimed to guarantee that the current project progress is going in the right direction. The 2nd Stakeholder meeting sparked new ideas on leveraging RWE for diabetes treatments and we are always open to new stakeholders in the project to help us achieve the best result,’’ explains Julia Mader, Associate Professor of Internal Medicine and diabetology at the Medical University of Graz and coordinator of the REDDIE project.
As the REDDIE project moves forward, we are excited to organize more Stakeholder meetings, uniting regulators, representatives from HTA bodies, patient associations, and authors of diabetes treatment guidelines to help ensure the most successful results for the REDDIE project.
REDDIE remains fully committed to aligning our efforts with the needs of the diabetes community and clinical practices while staying in line with regulatory standards. If you are interested in the project, feel free to reach out.
